Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case-control study

• Published in: BMC research notes Vol. 12; no. 1; p. 556
• Main Authors: Mata-Marín, José Antonio, Martínez-Osio, Moisés Hermilo, Arroyo-Anduiza, Carla I, Berrospe-Silva, María de Los Ángeles, Chaparro-Sánchez, Alberto, Cruz-Grajales, Itzel, Cruz-Herrera, Javier Enrique, Uribe-Noguez, Luis Antonio, Gaytán-Martínez, Jesus E, Jerónimo-Morales, Medardo
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.09.2019; BioMed Central; BMC
• Subjects: Adult; Age; Arthritis; Cardiovascular disease; Case studies; Case-Control Studies; CD4 antigen; Chronic obstructive pulmonary disease; Comorbidity; Comparative analysis; Coronary vessels; Demographic aspects; Diabetes; Diabetes mellitus; Drug therapy; Drugs; Family medical history; Heart failure; HIV; HIV patients; HIV Seropositivity - drug therapy; HIV Seropositivity - epidemiology; Human immunodeficiency virus; Humans; Hyperlipidemia; Hypertension; Kidney diseases; Liver diseases; Middle Aged; Obesity; Osteoarthritis; Patients; Polypharmacy; Prevalence; Research Note; Studies; Mexico; HIV; Comorbidity; Polypharmacy
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-019-4576-6

This study was to determine and compare the prevalences of polypharmacy and comorbidities in patients aged 50 years or older with those patients younger than 50 years in a Mexican population. One hundred and twenty-five patients were enrolled, 60 (48%) were aged 50 years or older. The median CD4+ cell counts were 509 cells/μL (interquartile range [IQR]: 324-730) for the older patients and 384 cells/μL (IQR: 262-562) (P = 0.021) for the younger patients. Viral suppression were significantly higher in the older group: 80% vs. 63% (P = 0.037). The number of comorbidities was significantly higher in the older group, with a median of 2 (IQR: 2-3) vs. 1 (IQR: 0-1) (P ≤ 0.001). After adjustment of the logistic regression model in the older group, the following comorbidities differed between the age groups: systemic arterial hypertension (odds ratio [OR]: 15.75; 95% confidence interval [CI] 3.49-71.05; P = < 0.001), diabetes mellitus (OR: 14.36; 95% CI 1.79-115.07; P = 0.001), osteoarthritis (OR: 10.33; 95% CI 2.88-37.05; P = < 0.001), hyperlipidemia (OR: 2.78; 95% CI 1.22-6.34; P = 0.001), and polypharmacy (OR: 6.58; 95% CI 3.01-14.39; P = 0.001).